Fluorouracil Treatment Via Colon for Colorectal Cancer
- Disease/Condition
- Colorectal Cancer
- Drug/Device/Intervention
- Colonic local administration of fluorouracil with enhanced adhesion
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- The Second Hospital of Nanjing Medical University
- Location
- Nanjing, China
- Phase
- Phase 2
- Start date
- May 01, 2024
- End date
- May 01, 2029
- Enrollment
- 40 participants
Objective response rate (according to RECIST1.1, investigator assessment)
Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive
 hydrogel presents a promising carrier for 5-FU to address challenges encountered with
 traditional administration methods. We propose an integrated approach utilizing colonic
 transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a
 thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the
 feasibility, safety, and efficacy of this approach for treating CRC.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06385418
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06385418 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Second Hospital of Nanjing Medical University and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.